Back to Search
Start Over
A phase I study of 4'-0-tetrahydropyranyladriamycin. Clinical pharmacology and pharmacokinetics.
- Source :
-
Cancer [Cancer] 1990 Nov 15; Vol. 66 (10), pp. 2082-91. - Publication Year :
- 1990
-
Abstract
- A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors. Twenty-six had minimal prior therapy (good risk), 23 had extensive prior therapy (poor risk), and six had renal and/or hepatic dysfunction. A total of 167 courses at doses of 15 to 70 mg/m2 were evaluable. Maximum tolerated dose in good-risk patients was 70 mg/m2, and in poor-risk patients, 60 mg/m2. The dose-limiting toxic effect was transient noncumulative granulocytopenia. Granulocyte nadir was on day 14 (range, 4-22). Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites. Urinary excretion of Pirarubicin in the first 24 hours was less than or equal to 10%. Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma. The recommended starting dose for Phase II trials is 60 mg/m2 IV bolus every 3 weeks.
- Subjects :
- Adult
Aged
Agranulocytosis chemically induced
Doxorubicin adverse effects
Doxorubicin pharmacokinetics
Doxorubicin pharmacology
Doxorubicin therapeutic use
Drug Administration Schedule
Female
Humans
Male
Middle Aged
Neoplasms drug therapy
Remission Induction
Stroke Volume drug effects
Doxorubicin analogs & derivatives
Neoplasms metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 0008-543X
- Volume :
- 66
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Cancer
- Publication Type :
- Academic Journal
- Accession number :
- 2224762
- Full Text :
- https://doi.org/10.1002/1097-0142(19901115)66:10<2082::aid-cncr2820661007>3.0.co;2-5